The Trump administration’s steep tariffs on Chinese imports are threatening to further destabilize hospitals’ bottom lines by ...

There were only five hospital M&A transactions during the first quarter of 2025 — a slump caused the Trump administration’s flurry of new policies and the resulting economic uncertainty. Hospitals are ...

Healthcare leaders might be too confident about their AI readiness, according to new research. It showed that 70% of leaders ...

The Trump administration aims to change the Medicare Drug Price Negotiation Program in a way that would delay when certain ...

The future of telehealth is trust, combined with patient education. As the market matures, all parties — providers, ...

Roche said it will expand existing sites and construct new U.S. manufacturing and R&D infrastructure in areas such as gene ...

In a new report, the Peterson Center on Healthcare made policy recommendations on reimbursement, access and data collection ...

Sanofi and Regeneron Pharmaceuticals drug Dupixent has won FDA approval for chronic spontaneous urticaria, introducing a new approach to the treatment of this inflammatory skin disorder.

The FDA laid out a three-year roadmap to phase out animal toxicity testing in drug research. In addition to organoids and lab ...

UnitedHealth Group took quite the tumble on Thursday and Medicare Advantage troubles seem to largely be at fault. Its shares fell by over 22% after its first quarter earnings on Thursday.